Amgen Inc (AMGN.O)
99.08USD
17 Jun 2013
$1.66 (+1.70%)
$97.42
$98.72
$100.09
$98.50
3,082,696
--
--
--
AMGN.O
About
Overall
| Beta: | 0.46 |
| Market Cap (Mil.): | $73,062.72 |
| Shares Outstanding (Mil.): | 749.98 |
| Dividend: | 0.47 |
| Yield (%): | 1.93 |
Financials
| AMGN.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 16.47 | 38.69 | 31.05 |
| EPS (TTM): | 5.91 | -- | -- |
| ROI: | 10.51 | 2.39 | 18.93 |
| ROE: | 23.95 | 3.60 | 19.82 |
Amgen share buybacks, drugs may fuel more stock gains - Barron's
- Amgen Inc , the world's largest biotechnology company, has plenty of room to grow despite a 43 percent jump in its share price over the past year, thanks to cost cuts, newer drugs and hefty share buybacks, Barron's said.
Amgen share buybacks, drugs may fuel more stock gains - Barron's
June 16 - Amgen Inc, the world's largest biotechnology company, has plenty of room to grow despite a 43 percent jump in its share price over the past year, thanks to cost cuts, newer drugs and hefty share buybacks, Barron's said.
Amgen says drug slowed ovarian cancer in trial
- Amgen Inc's trebananib drug for ovarian cancer extended the length of time that patients lived without the disease getting worse by about two months, meeting the main goal of a late-stage clinical trial, the company said on Wednesday.
UPDATE 1-Amgen says drug slowed ovarian cancer in trial
June 12 - Amgen Inc's trebananib drug for ovarian cancer extended the length of time that patients lived without the disease getting worse by about two months, meeting the main goal of a late-stage clinical trial, the company said on Wednesday.
Amgen says trebananib reduces risk of ovarian cancer in trial
June 12 - Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
Amgen melanoma drug improved survival by 21 pct in interim look
CHICAGO, June 1 - Data from a pivotal trial of Amgen Inc's experimental melanoma therapy shows that it improved survival by 21 percent for patients with advanced forms of the deadly skin cancer compared with a standard white blood cell-boosting drug.
Drugs from Amgen, others assessed by FDA as radiation treatments
- Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
Drugs from Amgen, others assessed by FDA as radiation treatments
May 1 - Drugs from Amgen Inc, Teva Pharmaceutical Industries and Sanofi that boost white blood cells are being evaluated by U.S. regulators as treatments for radiation exposure caused by a nuclear attack or accident.
Amgen first quarter sales disappoint, shares fall
- Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent.
UPDATE 3-Amgen first quarter sales disappoint, shares fall
April 23 - Amgen Inc on Tuesday reported first-quarter sales that fell short of Wall Street expectations for most of its biggest-selling medicines, and its shares fell more than 6 percent.
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $85.63 | +0.72 |
| Roche Holding Ltd. (ROG.VX) | CHF231.10 | +4.20 |
| Hospira, Inc. (HSP.N) | $36.42 | +0.18 |
| Novartis AG (NOVN.VX) | CHF67.75 | +0.85 |
| Shire PLC (SHP.L) | 2,095.00p | +13.00 |
| Shire PLC (3159084.L) | -- | -- |
| Bayer AG (BAYGn.DE) | €83.49 | +1.72 |
| Bayer AG (BAYE.F) | -- | -- |
| CHUGAI PHARMACEUTICAL CO., LTD. (4519.T) | ¥1,977 | -56.00 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 14,050.00₪ | +100.00 |
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Stock Traders Daily
|
$58.00
|
|
Provider: Stock Traders Daily
|
$495.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: Wright Reports
|
$472.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
